Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the world's leading biopharma companies.
The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 702 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cancer diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2018.
Chapter 3 provides an overview of the leading cancer diagnostic deals since 2018. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2018, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2018. The chapter is organized by specific cancer diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2018.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
- Understand deal trends since 2018
- Browse cancer diagnostic collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 702 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cancer diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2018.
Chapter 3 provides an overview of the leading cancer diagnostic deals since 2018. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2018, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2018. The chapter is organized by specific cancer diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2018.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Report Scope
Cancer Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.Cancer Diagnostic Collaboration and Licensing Deals includes:
- Trends in cancer diagnostic dealmaking in the biopharma industry
- Directory of cancer diagnostic deal records covering pharmaceutical and biotechnology
- The leading cancer diagnostic deals by value
- Most active cancer diagnostic licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - IntroductionChapter 6 - Cancer diagnostic dealmaking by technology type
Chapter 2 - Trends in cancer diagnostic dealmaking
Chapter 3 - Leading cancer diagnostic deals
Chapter 4 - Most active cancer diagnostic dealmakers
Chapter 5 - Cancer diagnostic contracts dealmaking directory
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2cureX
- 3B Pharmaceuticals
- 4bases
- 4D Path
- 1717 Life Science Ventures
- A2 Biotherapeutics
- A3P Biomedical
- Abbisko Therapeutics
- Abcam
- Abramson Cancer Center
- ABX
- Academic Breast Cancer Consortium
- Accudata Systems
- AccuStem Sciences
- Acibadem University
- Acrivon Therapeutics
- Adaptive Biotechnologies
- Adaptive Research
- ADC Therapeutics
- Advanced Accelerator Applications
- Advanced Nuclear Medicine Ingredients
- Agena Bioscience
- Agendia
- Agilent Technologies
- Agios Pharmaceuticals
- Aidence
- Aidoc
- Akoya Biosciences
- Alberta Health Services
- Alibaba Health
- Allarity Therapeutics
- Allelica
- Allogene Therapeutics
- Almac Diagnostics
- Alphageneron Pharmaceuticals
- Alverno Clinical Laboratories
- Ambry Genetics
- American Health Imaging
- Amgen
- Amoy Diagnostics
- AnchorDx
- Angle
- AnHeart Therapeutics
- Anixa Biosciences
- Anpac Bio-Medical Science
- Antisoma Therapeutics
- Apollomics
- Applied DNA Sciences
- ArcherDX
- Arizona State University
- AroCell
- Arrayus Technologies
- ARTBIO
- ArteraAI
- Artidis
- Artios Pharma
- ARTMS Product
- Arvinas
- Ashion Analytics
- Asieris MediTech
- Asieris Pharmaceuticals
- Assistance Publique-Hôpitaux de Paris
- AstraZeneca
- Astrin Biosciences
- Atlas Antibodies
- Atrin Pharmaceuticals
- Avera Health
- Avrobio
- BAMF Health
- Bayer
- Baylor Scott and White Research Institute
- BC Cancer Agency
- Becton Dickinson
- BeiGene
- Beijing Genomics Institute (BGI)
- Berry Oncology
- Bethyl Laboratories
- BGN Technologies
- Bicycle Therapeutics
- Bio-Rad Laboratories
- bioAffinity Technologies
- BioAgilytix
- Biocare Medical
- Biocartis
- Biocept
- BioCheetah
- Biocodices
- Biodesix
- Biofidelity
- BioGemex
- Biogenar
- Biognosys
- BioInvent
- BioLizard
- Biological Dynamics
- BioMark Diagnostics
- BioMarker Strategies
- BioNano Genomics
- BioNTech
- BioSkryb
- BioVolume
- Bird Foundation
- Blackford
- Bliss Biopharmaceutical
- Blu Biotech
- Blue Earth Diagnostics
- Boehringer Ingelheim
- BostonGene
- Bot Image
- BPGbio
- Bpifrance
- Bracco Imaging
- Brainomix
- Brazlex Medical Genetics
- Breath Diagnostics
- Brenus Pharma
- BriaCell Therapeutics
- Brigham and Women's Hospital
- BrightPath Biotherapeutics
- Bristol-Myers Squibb
- Broad Institute
- Bruker
- Burning Rock
- C2i Genomics
- Calviri
- Calyx
- Canadian Cancer Society
- Canadian Institutes of Health Research
- Cancer Research UK
- Cancer Targeted Technology
- CancerX initiative
- Capsulomics
- Cardiff University
- Caris Life Sciences
- Case Western Reserve University
- Castle Biosciences
- Cedars-Sinai Medical Center
- CeGaT
- Celcuity
- Celgene
- Cellgen Diagnostics
- CellMax Life
- Cellpath
- Celsius Therapeutics
- Centogene
- Centre for Imaging Technology Commercialization
- Centre for Probe Development and Commercialization
- Centre Leon Berard
- Cepheid
- Certis Oncology Solutions
- Champalimaud Foundation
- Champions Oncology
- Charles River Laboratories
- Children's Hospital Boston
- China Grand Pharma
- China Grand Pharmaceutical
- Christian Doppler Research Association
- ChromaCode
- Chronix Biomedical
- Chugai Pharmaceutical
- Cizzle Biotech
- CK Life Sciences
- Clarity Pharmaceuticals
- Clarix
- ClearNote Health
- Cleveland Clinic
- Cleveland University Hospitals
- Clinical Laserthermia Systems (CLS)
- Clovis Oncology
- Co-Diagnostics
- Coeptis Pharmaceuticals
- Cofactor Genomics
- Colorado Melanoma Foundation
- Columbia University
- Columbia University Medical Center
- ConcertAI
- Congenica
- Contextual Genomics
- Copenhagen University Hospital
- CoreBiome
- CorePath Laboratories
- CorePlus
- Cornell University
- Criterium
- Crosscope
- CSI Laboratories
- CStone Pharmaceuticals
- Culmination Bio
- Curasight
- CureMetrix
- Curium
- Curta
- Cypre
- Cytogen
- Daiichi Sankyo
- Dana-Farber Cancer Institute
- Danish Center for Strategic Research into Type 2 Diabetes
- DarwinHealth
- Day One Biopharmaceuticals
- Debiopharm
- Decipher Biosciences
- deCODE Genetics
- Deep Bio
- Deepcell
- Delphi Diagnostics
- Dendreon
- Denovo Biopharma
- Densitas
- Department of Defense
- Detect-Ion
- DiaCarta
- DIAN Diagnostics
- Diannei Biotechnology
- Diaprost
- Diatech Pharmacogenetics
- DoMore Diagnostics
- DuChemBio
- Duke University
- Dxcover
- DYNEX Technologies
- Early is Good
- EchelonDx
- Eckert & Ziegler
- EDP Biotech
- EDX Medical
- Eisai
- Elephas
- Elevation Oncology
- Eli Lilly
- EmeritusDX
- Emit Imaging
- Emory University
- Endoluxe
- Enigma Biomedical
- Epic Sciences
- Epiphany Dermatology
- Epizyme
- Erasmus University Medical Center
- ESSA Pharma
- Essen University Hospital
- Euformatics
- Eureka Eurostars
- Eurobio Scientific
- European Commission
- European Innovation Council
- European Institute of Oncology (EIO)
- European Organization for Research and Treatment of Cancer
- Exact Sciences
- Exai Bio
- Exigent Research
- EXINI Diagnostics
- Exosome Diagnostics
- Exosome Sciences
- F-Star Therapeutics
- Factorial Diagnostics
- Falco
- Farcast Biosciences
- Ferronova
- Ferrum Health
- Fibrogen
- FivepHusion
- Five Prime Therapeutics
- Flagship Biosciences
- Flare Therapeutics
- Flatiron Health
- Florida Theranostics
- Focal Healthcare
- FogPharma
- Fondation Cancer
- Fondatioun Kriibskrank Kanner
- Foresight Diagnostics
- Fortis Therapeutics
- Foundation Medicine
- Fox Chase Cancer Center
- Francis Crick Institute
- Freenome
- Friends of Cancer Research
- Fujifilm medical systems
- Fulgent Genetics
- Fuzionaire Diagnostics
- Fuzionaire Radioisotope Technologies
- GANZIMMUN Diagnostics
- GC Genome
- GE Healthcare
- GeneCentric Therapeutics
- GeneNews
- Genentech
- GeneQuantum Healthcare
- Geneseeq
- GenesisCare
- Genetron Health
- Genome Canada
- Genome Diagnostics
- GenomeDx
- Genomic Testing Cooperative
- Genomill Health
- Genomoncology
- Georgetown University
- German Cancer Research Center
- German Federal Ministry of Education and Research
- Gestalt Diagnostics
- Gibson Oncology
- Global Lung Cancer Coalition
- GNS Healthcare
- Government of Canada
- Grail
- Gritstone Bio
- GSK
- Guardant Health
- Guerbet
- Guided Therapeutics
- Gyros Protein Technologies
- Hainan Sinotau Pharmaceutical
- Halo Dx
- HALO Precision Diagnostics
- Harbinger Health
- Harvard Medical School
- Harvard University
- Haystack Oncology
- HealthCare Konnect
- Hebrew University of Jerusalem
- Helio Genomics
- Helio Health
- Henan Cancer Hospital
- Hengrui Therapeutics
- Henlius Biotech
- Henry M. Jackson Foundation
- Heska
- HiberCell
- HiloProbe
- Hoag Memorial Hospital Presbyterian
- Holobeam Technologies
- Hologic
- Horizon Discovery
- Horizon Europe
- Hospital Clinic of Barcelona
- HotSpot Therapeutics
- HTG Molecular Diagnostics
- Huma
- Hummingbird Bioscience
- Huntsman Cancer Institute
- Ibex Medical Analytics
- IBM
- IBM Watson Health
- iCAD
- ICAN
- Idaho Urologic Institute
- Ikonisys
- Ikonopedia
- Illumina
- Image Analysis
- ImaginAb
- IMBdx
- Immunovia
- IMPACT Therapeutics
- IncellDx
- Incyte
- Indiana University
- Indica Labs
- Indivumed
- Industrial Centre for Artificial Intelligence Research in Digital Diagnostics
- Inflammatory Breast Cancer Research Foundation
- Inform Diagnostics
- Inivata
- Innoplexus
- Innovate BC
- Innovate UK
- Inocras
- Inovio Pharmaceuticals
- InSightec
- InSphero
- Institut Curie
- Institute for Bioscience and Biotechnology Research
- Institut Gustave Roussy
- Institut Paoli-Calmettes
- Integrated Biobank of Luxembourg
- Intermountain Healthcare
- International Association for the Study of Lung Cancer
- International Centers for Precision Oncology Foundation
- Intezyne
- Invenio Imaging
- inviCRO
- Invitae
- InVivoScribe
- Isotopia Molecular Imaging
- Item
- ITM Isotopen Technologien
- Janssen-Cilag
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Pharmaceutica NV
- Janssen Research & Development
- Jefferson Healthcare
- JelloX Biotech
- Jiangsu Chia Tai Tianqing Pharmaceutical
- Johns Hopkins University
- Johnson & Johnson
- Johnson & Johnson Innovation
- John Wayne Cancer Institute
- Juntendo University
- Kanazawa University
- Karolinska University Hospital
- Kartos Therapeutics
- Karyopharm Therapeutics
- KDx Diagnostics
- Kephera Diagnostics
- KEW
- Kheiron Medical Technologies
- Kite Pharma
- Kiyatec
- Korea Pharma
- Kronos Bio
- Kura Oncology
- Laboratory Corporation of America
- Lantern Pharma
- Lantheus Holding
- Lantheus Medical Imaging
- Latvian Institute of Organic Synthesis
- Lawson Health Research Institute
- Leap Therapeutics
- Lee Moffitt Cancer Center
- Leica Biosystems
- Les Laboratoires Servier
- Leucid Bio
- Lexent Bio
- LifeOmic
- Life Raft Group
- LifeSensors
- LifeX Ventures
- Lightpoint Medical
- Li Ka Shing Foundation
- LineaRx
- Liquid Biosciences
- Lisata Therapeutics
- Little Warrior Foundation
- Loxo Oncology
- Lucence
- Lucid Diagnostics
- Luminex
- Lunaphore
- Lung Cancer Initiative
- Lunit
- Lurie Children's Hospital of Chicago
- M42
- Magic Leap
- Magle Chemoswed
- Magnetic Insight
- Mainz Biomed
- Mammoth Biosciences
- MapKure
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Massachusetts Life Sciences Center
- Mauna Kea Technologies
- Max Planck Institute for Multidisciplinary Sciences
- Mayo Clinic
- McMaster University
- MD Anderson Cancer Center
- MDxHealth
- Medexus Pharmaceuticals
- Medial EarlySign
- MEDIAN Technologies
- Medical University of Graz
- Medidata Solutions
- Medipath
- Mediso
- Melanoma Research Alliance
- Memorial Sloan Kettering Cancer Center
- Merck and Co
- Merck KGaA
- Merus
- Metabiomics
- Metabolon
- Metafora Biosystems
- MGI Tech
- Michelson Center
- Microsoft
- Mie University
- Milburn Foundation
- MindPeak
- Minerva Imaging
- MIODx
- Mirati Therapeutics
- miR Scientific
- MiRXES
- MITRO Biotech
- Moderna
- Molecular Health
- Molecular Targeting Technologies
- Monoceros Biosystems
- Mount Sinai Health System
- MP Group
- mProbe Laboratories
- MRM Proteomics
- MSD
- Multimmune
- Munich Technical University
- Myriad Genetics
- Nano-X Imaging
- NanoMab Technology
- Nanostics Precision Health
- NanoString Technologies
- Natera
- National Cancer Center
- National Cancer Center of Japan
- National Cancer Centre Singapore
- National Cancer Institute
- National Cancer Institute of Mexico
- National Institutes of Health
- National Institutes of Health Clinical Center
- National Organization for Rare Disorders
- National Physical Laboratory
- Naval Medical Research Center
- Naveris
- Navidea Biopharmaceuticals
- Nektar Therapeutics
- NeoDynamics
- Neogap Therapeutics
- Neogenomics
- Neosoma
- NeraCare
- Neuvogen
- New Horizon Health
- New Jersey Urology
- NewStem
- NGeneBio
- Nico
- Nihon Medi-Physics
- Nippon Kayaku
- Nonacus
- Norgine
- Noria Therapeutics
- Northeastern University
- Northwestern University
- NovAccess Global
- NovAliX
- Novarad
- Novartis
- NovaScan
- NovellusDx
- Novigenix
- Novogene
- NRG Oncology
- nRichDX
- NTT Data
- Nucleai
- Nucleix
- Nuclidium
- NuProbe
- NX Development
- NYU Langone Medical Center
- Ochin
- Ohio State University
- Olink Proteomics
- OmiCure
- Oncidium Foundation
- Oncimmune
- OncoAssure
- OncoCyte
- OncoDNA
- OncoGenesis
- Oncoheroes Biosciences
- OncoHost
- Oncology Venture
- OncoNano Medicine
- Oncovet
- OncXerna Therapeutics
- OnLume Surgical
- Ono Pharmaceutical
- Onsite Women’s Health
- Ontario Institute for Cancer Research
- Optellum
- OracleBio
- Oregon Health Sciences University
- OrigiMed
- Osaka University
- OSE Immunotherapeutics
- Oslo University Hospital
- Ospedale Pediatrico Bambino Gesu
- Owkin
- Owlstone Medical
- Oxford Nanopore Technologies
- Pacific Biosciences
- Paige
- Pancreatic Cancer Early Detection Consortium
- Parthenon Therapeutics
- PathAI
- PathGroup
- Pathnova Laboratories
- Paul Scherrer Institute
- PAVmed
- Pennsylvania State University
- PentixaPharm
- Pepscan
- Personal Genome Diagnostics
- Personalis
- Pfizer
- Pfizer Canada
- PharmaLogic
- PHC
- PhenoVista Biosciences
- Phillips-Medisize
- Philochem
- Phoenix Molecular Designs
- Photocure ASA
- Phytronix Technologies
- PierianDx
- Pierre Fabre
- Pillar Biosciences
- Pionyr Immunotherapeutics
- PixCell Medical
- Planet Innovation
- Planmed
- Plus Therapeutics
- PMV Pharma
- Point32Health
- POINT Biopharma
- Polarean Imaging
- Precipio Diagnostics
- PreciseDx
- Precision for Medicine
- Precision Pathology Services
- Predicine
- Predictive Technology Group
- PrediLife
- Premier Inc
- PreMIT
- Prenetics
- Preora Diagnostics
- Prescient Medical
- Previse
- Progenics Pharmaceuticals
- Promega
- ProPath
- Prophase Labs
- Proscia
- Protean BioDiagnostics
- ProteoMediX
- Providence Saint John's Health Center
- PSI CRO
- PT Elion Medika
- Puerto Rico Government
- Puma Biotechnology
- Purdue Research Foundation
- QED Therapeutics
- QIAGEN
- Qlarity Imaging
- QT Imaging
- Qualigen
- Quanterix
- Quantum Leap Health Care Collaborative
- Quebec Heart and Lung Institute
- Queensland University of Technology
- Queens University Belfast
- Quest Diagnostics
- Qure Healthcare
- R-Pharm
- Race Oncology
- Radboud University Nijmegen Medical Centre
- Radiomedix
- Radiopharm Theranostics
- Radius Health
- RadNet
- Rarecells
- Ratio Therapeutics
- RAW
- RayBiotech
- Realm IDx
- Recursion
- RefleXion Medical
- Relay Therapeutics
- Renji Hospital
- Renown Institute for Health Innovation
- Resolution Bioscience
- RevealDx
- Reveal Genomics
- Richard Wolf Medical Instruments
- Roche
- Roche Diagnostics
- Roche Molecular Systems
- Roswell Park Cancer Institute
- ROTOP Pharmaka
- Royal Philips Electronics
- Rubix LS
- Rutgers Cancer Institute of New Jersey
- SAGA Diagnostics
- Saladax Biomedical
- Sanofi
- Sarah Cannon Research Institute
- Satisfai Health
- Scandion Oncology
- SciBase
- Scintomics
- Screenpoint Medical
- Sebela Pharmaceuticals
- Sebia
- Secarna Pharmaceuticals
- SeekIn
- Sengenics
- SEngine Precision Medicine
- Shanghai Pharmaceutical
- Shenzhen Chipscreen Biosciences
- Sherlock Biosciences
- Shuttle Pharmaceuticals
- Shuwen Biotech
- Siemens Healthineers
- Signet Medical Solutions
- SimBioSys
- Simsen Diagnostics
- Sirona Medical
- Sirtex Medical
- Skane University Hospital
- Skyline Diagnostics
- SkylineDX
- Skysong Innovations
- Smiths Medical
- Sofie Biosciences
- Solis Mammography
- SomaLogic
- Sona Nanotech
- Sonrai Analytics
- SOPHiA Genetics
- Soricimed Biopharma
- SOTERIA Precision Medicine Foundation
- Spectrum Pharmaceuticals
- Spectrum Solutions
- Spesana
- SST Group
- St. Jude Children's Research Hospital
- Stanford University
- Starpharma
- Statera Biopharma
- STRATIFYER Molecular Pathology
- Sunnybrook Research Institute
- Susan G. Komen for the Cure
- Swiss Institute of Allergy and Asthma Research
- Swiss Institute of Bioinformatics (SIB)
- Syndax Pharmaceuticals
- Sysmex
- Sysmex Inostics
- T-Cure Bioscience
- Take2
- Takeda Pharmaceutical
- Tampere University Hospital
- Tasly Pharmaceuticals
- Techcyte
- Tel Aviv University
- TeleMammography Specialists
- Telix Pharmaceuticals
- Telo Genomics
- Tempus
- TeraRecon
- Texas A&M University
- The Parker Institute For Cancer Immunotherapy
- Theragnostics
- Theralink Technologies
- TheraPanacea
- Therapixel
- Thermo Fisher Scientific
- The Technical University Of Munich
- ThinkCyte
- Thomas Jefferson University
- Todos Medical
- Tor Vergata University Hospital
- TP Therapeutics
- Transcenta
- TransCode Therapeutics
- TriSalus Life Sciences
- TScan Therapeutics
- TumorGen
- TwinStrand Biosciences
- Twist Bioscience
- uBiome
- UK Government
- Ultivue
- Unilabs
- Uni Targeting Research
- Universal DX
- University College London
- University Health Network
- University Hospital Bispebjerg
- University Medical Center Hamburg-Eppendorf
- University of Antwerp
- University of Arkansas
- University of Augsburg
- University of Barcelona
- University of Birmingham
- University of Bonn
- University of California
- San Diego
- University of California Berkeley
- University of California Irvine
- University of California Los Angeles
- University of California San Francisco
- University of Chicago
- University of Florida
- University of Greifswald
- University of Heidelberg
- University of Illinois
- University of Lausanne
- University of Leeds
- University of Louisville
- University of Manchester
- University of Massachusetts Medical School
- University of Miami
- University of Michigan
- University of Milano-Bicocca
- University of Newcastle
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Queensland
- University of Rostock
- University of Sheffield
- University of Southampton
- University of South Carolina
- University of Texas Southwestern Medical Center
- University of Virginia
- University of Washington
- UPMC
- Urology Centers of Alabama
- Urology San Antonio
- UroPartners
- UroViu
- US Oncology
- US Radiology Specialists
- Varian Medical Systems
- Vect-Horus
- Vela Diagnostics
- Veracyte
- Vida Diagnostics
- Vidence
- ViennaLab Diagnostics
- Viewpoint Molecular Targeting
- Vincere Cancer Center
- Virginia Tech Intellectual Properties
- Visiopharm
- VolitionRX
- Volpara Solutions
- VyGen-Bio
- Wallace H. Coulter Foundation
- Waseda University
- Washington University in St Louis
- Watchmaker Genomics
- Weihai Weigao Medical Devices
- Weizmann Institute
- WellDyne
- Wellmarker Bio
- West German Study Group
- Whiterabbit
- Whitman-Walker Institute
- Windber Research Institute
- Windsong Radiology
- Wyss Institute
- Xencor
- Xiamen Encheng Group
- XtalPi
- Xylonix
- Yale School of Medicine
- Yale University
- Yemaachi Biotech
- Yitu Medical
- ZAI Laboratory
- Zealand University Hospital
- Zomedica
- zPREDICTA
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
